ASYMMETRIC DIMETHYLARGININE

Loo Hariyanto Raharjo

Abstract


Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a key chemical to endothelial and hence cardiovascular health. ADMA
concentration is elevated in patients with end-stage renal disease (ESRD), in part because it is excretedvia the kidneys.

 


Keywords


Asymmetric dimethylarginine (ADMA); nitric oxide; endothelial and cardiovascular hence; end-stage renal disease

Full Text:

PDF

References


Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven

GM 2001 Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.

Am J Cardiol 88:1201–1203 Baylis C, Mitruka B, Deng A: Chronic

blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage.J Clin Invest 90:278 - 281, 1992

Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-

Boger SM (2000). "LDL cholesterol upregulates synthesis of asymmetrical

dimethylarginine in human endothelial cells: involvement of S-

adenosylmethionine-dependent methyltransferases". Circ Res 87 (2): 99-

Cooke, J.P. and D.W. Losordo, Nitric oxide and angiogenesis. Circulation, 2002. 105(18): p. 2133-5.

Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K (1997). "Effect of supplemental oral L-arginine on exercise capacity in patients with stable

angina pectoris". Am J Cardiol 80 (3): 331-3.

Fard, A., et al., Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes [In Process Citation]. Arterioscler

Thromb Vasc Biol, 2000. 20(9): p. 2039-44.

Janatuinen T, Laakso J, Laaksonen R,Vesalainen R, Nuutila P, Lehtimaki T,

Raitakari OT, Knuuti J (2003). "Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood

flow in young adults". Vasc Med 8 (3):185-9.

Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM,

Frolich JC 1999 Asymmetric dimethylarginine plasma concentrationsdiffer in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594–600

R, et al.: Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997, 96(4):1282-1290

Boger, R.H. and S.M. Bode-Boger, Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and

cardiovascular diseases. Semin Thromb Hemost, 2000. 26(5): p. 539-45.

London GM, Drüeke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int51 : 1678- 1695,1997

Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701,1974

Moncada S, Higgs A: The L-arginine- nitric oxide pathway. N Engl J Med

:2002 -2012, 1993

Najbauer, J., et al., Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA

are efficiently recognized by methyltransferase(s) modifying arginine in

numerous proteins. J Biol Chem, 1993. 268(14): p. 10501-9.

Rees DD, Palmer RM, Hodson HF, Moncada S: A specific inhibitor of nitric

xide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96:418 -424, 1989

Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo

SH (1996). "Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure". Circulation 93 (12): 2135-41

Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke

JP, Reaven GM, Tsao PS 2002 Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420–1426

Stuhlinger, M., et al., Endothelial dysfunction induced by hyperhomocyst(e)inemia - Role of ADMA. 2003: Stanford.

Surdacki, A., et al., Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential

hypertension. J Cardiovasc Pharmacol, 1999. 33(4): p. 652-8. Sydow, K., et al., ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia:effects of L-arginine and B vitamins.

Cardiovasc Res, 2003. 57(1): p. 244-52. Teerlink, T., et al., Estrogen replacement therapy lowers plasma levels of asymmetric dimethylarginine in healthy postmenopausal women. Clin Sci (Lond),

Tsao, P.S., et al., Nitric oxide regulates monocyte chemotactic protein-1.

Circulation, 1997. 96(3): p. 934-40.

Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, et al.:

Dietary L-arginine supplementation normalizes platelet aggregation in

hypercholesterolemic humans. J Am Coll Cardiol 1997, 29(3):479-485




DOI: http://dx.doi.org/10.30742/jikw.v2i1.77

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Loo Hariyanto Raharjo

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License